1. Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice. Issue 1 (December 2017) Authors: He, Wenqian; Chen, Chi-Jene; Mullarkey, Caitlin; Hamilton, Jennifer; Wong, Christine; Leon, Paul; Uccellini, Melissa; Chromikova, Veronika; Henry, Carole; Hoffman, Kevin; Lim, Jean; Wilson, Patrick; Miller, Matthew; Krammer, Florian; Palese, Peter; Tan, Gene Journal: Nature communications Issue: Volume 8:Issue 1(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Development of next generation hemagglutinin-based broadly protective influenza virus vaccines. (August 2018) Authors: Nachbagauer, Raffael; Palese, Peter Journal: Current opinion in immunology Issue: Volume 53(2018) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. H-103 Towards a universal influenza virus vaccine. (April 2018) Authors: Palese, Peter Journal: Journal of acquired immune deficiency syndromes Issue: Volume 77(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model. Issue 1 (December 2018) Authors: Bailey, Mark; Duehr, James; Dulin, Harrison; Broecker, Felix; Brown, Julia; Arumemi, Fortuna; Bermúdez González, Maria; Leyva-Grado, Victor; Evans, Matthew; Simon, Viviana; Lim, Jean; Krammer, Florian; Hai, Rong; Palese, Peter; Tan, Gene Journal: Nature communications Issue: Volume 9:Issue 1(2018) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Issue 1 (January 2020) Authors: Bernstein, David I; Guptill, Jeffrey; Naficy, Abdollah; Nachbagauer, Raffael; Berlanda-Scorza, Francesco; Feser, Jodi; Wilson, Patrick C; Solórzano, Alicia; Van der Wielen, Marie; Walter, Emmanuel B; Albrecht, Randy A; Buschle, Kristen N; Chen, Yao-qing; Claeys, Carine; Dickey, Michelle; Dugan, H... Journal: Lancet infectious diseases Issue: Volume 20:Issue 1(2020) Page Start: 80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection. (7th November 2013) Authors: Zamarin, Dmitriy; Holmgaard, Rikke; Subudhi, Sumit; Mansour, Mena; Palese, Peter; Merghoub, Taha; Wolchok, Jedd D; Allison, James P Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. (March 2012) Authors: Zamarin, Dmitriy; Palese, Peter Journal: Future microbiology Issue: Volume 7:Number 3(2012) Page Start: 347 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1–2 randomised controlled trial. Issue 7 (July 2022) Authors: Folschweiller, Nicolas; Vanden Abeele, Carline; Chu, Laurence; Van Damme, Pierre; García-Sastre, Adolfo; Krammer, Florian; Nachbagauer, Raffael; Palese, Peter; Solórzano, Alicia; Bi, Dan; David, Marie-Pierre; Friel, Damien; Innis, Bruce L; Koch, Juliane; Mallett, Corey P; Rouxel, Ronan Nicolas; S... Journal: Lancet infectious diseases Issue: Volume 22:Issue 7(2022) Page Start: 1062 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Issue 26 (9th June 2022) Authors: Duc Dang, Anh; Dinh Vu, Thiem; Hai Vu, Ha; Thanh Ta, Van; Thi Van Pham, Anh; Thi Ngoc Dang, Mai; Van Le, Be; Huu Duong, Thai; Van Nguyen, Duoc; Lawpoolsri, Saranath; Chinwangso, Pailinrut; McLellan, Jason S.; Hsieh, Ching-Lin; Garcia-Sastre, Adolfo; Palese, Peter; Sun, Weina; Martinez, Jose L.; G... Journal: Vaccine Issue: Volume 40:Issue 26(2022) Page Start: 3621 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. (March 2022) Authors: Pitisuttithum, Punnee; Luvira, Viravarn; Lawpoolsri, Saranath; Muangnoicharoen, Sant; Kamolratanakul, Supitcha; Sivakorn, Chaisith; Narakorn, Piengthong; Surichan, Somchaiya; Prangpratanporn, Sumalee; Puksuriwong, Suttida; Lamola, Steven; Mercer, Laina D.; Raghunandan, Rama; Sun, Weina; Liu, Yong... Journal: EClinicalMedicine Issue: Volume 45(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗